Investigational drug · Phase 3
BBP-418
Also called: ribitol
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), LGMD2I.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "BBP-418"
First trial start
2021
Feb 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBP-418", any sponsor or status.
Conditions studied
As listed on its trial records.
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
- LGMD2I
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BBP-418" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)Pivotal-lookingActive, not recruiting
ML Bio Solutions, Inc.Industry
NCT05775848 · 112 participants · Start May 31, 2023 · Primary completion Sep 2027
Drug: BBP-418 (ribitol) · For: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Sites: Little Rock, Arkansas; Irvine, California; Aurora, Colorado · 21 sites in all
- Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9Pivotal-lookingActive, not recruiting
ML Bio Solutions, Inc.Industry
NCT07678775 · 107 participants (planned) · Start Jun 5, 2026 · Primary completion Oct 2030
Drug: BBP-418 (ribitol) · For: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Sites: Little Rock, Arkansas; Orange, California; Aurora, Colorado · 20 sites in all
- Study of BBP-418 in Patients With LGMD2IActive, not recruiting
ML Bio Solutions, Inc.Industry
NCT04800874 · 14 participants · Start Feb 18, 2021 · Primary completion Nov 1, 2026
Drug: BBP-418 · For: LGMD2I
Sites: Richmond, Virginia
Newest research
PubMed records naming it or its code names, newest first.
- Metabolomic assessment of nitrogen mustard and 2-chloroethyl ethyl sulfide effects on human dermal fibroblast cell line.
Sertoglu E, Kirlangic OF, Ortatli M, et al. · Cytotechnology 2026
- Phosphonomethyl (Thio)Phosphonamidite Reagents for the Construction of Phosphonylmethyl Phosphono(Di)Thioate Mono- and Diesters.
Balik P, Steneker R, Marel GAV, et al. · Chemistry 2026
- Nucleoside analogs containing an imino-ribitol sugar exhibit a distinctive pattern of interference with RNA synthesis by the Dengue virus polymerase.
Deshpande S, van Hameren AJB, Wood JM, et al. · Antiviral Res 2026
- Integrating atomistic recognition insights with experimental biosensing: A recombinant phage RBP-based SERS platform for Staphylococcus aureus.
Erdogdu B, Dokuz S, Çalk Kayiş E, et al. · Biosens Bioelectron 2026
- One-pot enzymatic synthesis of the sugar nucleotide CDP-ribitol.
Akkad S, Wan EW, Maddison A, et al. · RSC Chem Biol 2026
- Urinary metabolomics profile in children with ureteropelvic junction obstruction.
da Silva LHF, Mello MF, Kataoka FGH, et al. · Metabolomics 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.